2月27日，《证券日报》记者从国内口腔数字化领域企业爱迪特（301580）获悉，该公司以产业战略投 资人身份完成对上海央山医疗科技有限公司(以下简称"央山医疗")Pre-A+轮战略投资。此次合作将联动 爱迪特的产业资本与渠道资源，以及央山医疗在齿科硬科技领域的研发能力，聚焦"材料+设备+服 务"全链条生态构建。 投资完成后，爱迪特将依托其深耕齿科领域近二十年的产业基础，从市场渠道、产业落地等方面为央山 医疗提供支持，推动双方资源融合，加快数字化齿科生态闭环落地。 作为投资方，爱迪特主营口腔修复材料及数字化解决方案，已形成完整的口腔材料与设备研发、生产、 销售体系，核心产品包括氧化锆瓷块、玻璃陶瓷等口腔修复材料，以及CAD/CAM等数字化设备，产品 覆盖全球120多个国家和地区，境外收入占比近70%。其在数字化种植修复领域的技术积累与全球化营 销网络，将为央山医疗的商业化推进提供支持。 被投资方央山医疗专注于齿科硬科技领域，聚焦机器人、人工智能及无源类创新医疗（002173）器械的 研发与产业化，主要为口腔及颌面外科手术提供全流程解决方案。该公司核心团队具有国际化背景，成 员来自国内外顶尖高校、科研机构及行业龙 ...

一是深挖"非共识"的增长潜力。"若待上林花似锦，出门俱是看花人。"伟大的公司，往往在没人看 得懂、巨头看不上的时候拼命生长。无论是生物医药的爆发增长，还是AI在垂直领域的快速渗透， 裂缝中生长的机会，才有可能创造真正的Alpha。我们坚持寻找在大趋势之下，具备"第一"潜能或 者"唯一"稀缺性的企业。 CAN PART ? 骏 马 启 新 · 创 赢２０２６ 证券时报。全国创投协会联盟 National Alliance of Venture Capilal Associations 業 服 T l 江远投资创始 在周期换挡与科技跃迁交织的当下，新兴VC机构需要思考如何在范式转变的过程中，持续识别价 值、创造增量。 2025年，是江远投资深度聚焦、笃行不怠的一年。我们围绕医疗健康和科技两大方向，在生物医 药、AI应用、先进制造等细分领域，以精准追投+前瞻布局的方式出手近40次，近六成新增项目投 在A轮或更早期。 作为一家创业型VC，江远投资希望与优秀创业者同频共振，成为他们最早或者最重要的合作伙伴。 VC的本质，是在平均数之外寻找异质性，在混沌中发掘可能性，在泥泞里创造确定性。 责编：万健祎 校对： 廖胜超 版 ...

Group 1 - The core viewpoint of the news is the establishment of the Shanghai Futeng Huming Private Equity Fund, which focuses on the healthcare sector, marking a significant step in Shanghai's investment in the biopharmaceutical industry and signaling the opening of a new value investment window in this field [1][2]. - The fund has a first-phase fundraising scale of 410 million yuan and has completed its first investment in Xihua Testing, a global integrated drug research and development outsourcing service company [1][2]. - The establishment of the fund is a result of deepening cooperation between Shanghai and Sanming, leveraging Sanming's innovative experience in medical reform and Shanghai's international resources [1][2]. Group 2 - Futeng Capital has already invested in several innovative companies in the healthcare sector, including leading firms in brain-computer interfaces and gene therapy, covering various fields such as innovative drugs and high-end medical devices [2]. - The fund will focus on growth and mature stage projects with clear clinical needs and commercial viability, employing strategies like "old shares + capital increase" and "mergers and acquisitions" to empower enterprises [2][3]. - The fund aims to leverage Shanghai Guotou's advantages in policy alignment and long-term capital to support portfolio companies in their international development paths and to attract more strategic partners for a sustainable healthcare investment ecosystem [3].

Core Viewpoint - The establishment of the Shanghai Futeng Huming Private Equity Fund marks a significant step in Shanghai's investment in the biomedical industry, indicating the opening of a new value investment window in this sector [2][3]. Group 1: Fund Establishment and Collaboration - The fund, initiated by Shanghai Guotou and Sanming Investment Group, has completed a fundraising of 410 million yuan and made its first investment in Xihua Testing [2]. - This initiative represents a deepening collaboration between Shanghai and Sanming, leveraging Sanming's innovative experience in medical reform and Shanghai's resource advantages to create a new ecosystem for cross-regional healthcare investment [3]. Group 2: Investment Focus and Strategy - Futeng Capital has already invested in several innovative companies in the healthcare sector, including leading firms in brain-computer interfaces and gene therapy, covering various fields such as innovative drugs and high-end medical devices [4]. - The fund will focus on growth and mature stage projects with clear clinical needs and commercialization potential, employing strategies like "old shares + capital increase," "mergers and acquisitions," and "cross-border expansion" to empower companies [4]. Group 3: First Investment and Global Reach - The fund's first investment was in Xihua Testing, a global drug research and development outsourcing service provider, which will enhance its technical platform and expand international business [5]. - This investment is part of a "three-level linkage" mechanism that emphasizes the role of capital in driving industry collaboration and aims to elevate China's medical research service's influence in the global value chain [5]. Group 4: Future Development and Ecosystem Building - The fund will leverage Shanghai Guotou's advantages in policy alignment, industry resources, and long-term capital to support portfolio companies in their international development paths [7]. - There are plans to attract more strategic partners to build an open and sustainable investment landscape in the healthcare sector, contributing to the high-quality development of the biomedical industry in Shanghai and nationwide [7].

Group 1 - The core viewpoint of the article is that Zhuozheng Medical (2677.HK) is launching its IPO with a strong financial performance, contrasting with the industry's challenges [1] - The IPO will take place from January 29 to February 3, 2026, with a global offering of 4.75 million shares priced between HKD 57.7 and HKD 66.6 [1] - Zhuozheng Medical has achieved revenue growth from CNY 470 million in 2022 to CNY 690 million in 2023, and projected CNY 960 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [1] - The company's gross profit has increased significantly, from CNY 43.98 million in 2022 to CNY 130 million in 2023, and projected CNY 230 million in 2024, with a CAGR of 126.7% [1] - Zhuozheng Medical is expected to turn profitable in 2024, with adjusted net profits improving from a loss of CNY 1.23 billion in 2022 to a profit of CNY 10.7 million in 2024 [1] - The net cash flow from operating activities has shown steady growth, increasing from CNY 6.86 million in 2022 to CNY 12.4 million in 2023, and projected CNY 17.1 million in 2024 [1] Group 2 - Notable cornerstone investors in the IPO include leading third-party testing company Kingmed Diagnostics and He Xiaopeng, founder of Xpeng Motors, enhancing Zhuozheng Medical's IPO [2] - Several Tencent-affiliated listed companies are participating in the cornerstone investment, including Minglue Technology, Weimeng Group, Kuro Game, and Shouhui Group [2]

Core Viewpoint - Zhejiang Shuju Culture (600633) has experienced a slight decline in stock price, closing at 13.43 yuan, down 1.18% from the previous week, with a total market capitalization of 17.03 billion yuan [1] Company Announcements Summary - The company’s wholly-owned subsidiary, Hangzhou Bianfeng Network Technology Co., Ltd., has committed to invest 18 million yuan in the Chengdu Jichuang Chengyuan Venture Capital Fund, with an initial payment of 7.2 million yuan [1] - The total subscription amount for the fund is 208 million yuan, with Bianfeng Network holding an 8.65% stake [1] - The fund primarily focuses on investments in healthcare and advanced technology sectors and has completed private fund registration as of November 3, 2025 [1] - This investment aims to expand opportunities in cutting-edge fields and enhance the company's industrial layout, with no significant adverse impact on operations [1] - The company has participated in multiple private fund investments, some of which have entered liquidation or completed project investments [1]

Core Insights - Morgan Stanley will host the fifth Global Healthcare Industry Shanghai Conference from October 16 to 17, focusing on investment trends, industry innovation, and financing in the Chinese healthcare sector [1] - The Chinese healthcare industry has seen significant growth, driven by strong licensing deals for innovative drugs, solid fundamentals of biotech and pharmaceutical companies, and favorable domestic policies [1] - Shanghai is recognized as a hub for the healthcare industry in China, with a strong research and development capability, and local innovative pharmaceutical companies leading in financing transactions [1] Investment Trends - Investor interest in Chinese healthcare companies is rising due to the large population base, rapidly expanding market size, and improving innovation capabilities of Chinese firms [2] - Morgan Stanley emphasizes its commitment to enhancing healthcare investment banking services to support both domestic and international clients [2] Event Highlights - The conference will feature over 170 one-on-one or small group investor dialogues, providing a platform for business leaders and investors to exchange views and identify new opportunities in the global healthcare landscape [1] - Morgan Stanley also hosts the largest annual healthcare investment conference in San Francisco, attracting over 600 listed and private companies and more than 8,000 participants [2]

Group 1 - The company Pianzaihuang (600436.SH) announced that its wholly-owned subsidiary, Zhangzhou Pianzaihuang Investment Management Co., Ltd., plans to invest 200 million RMB as a limited partner, accounting for 20% of the target fundraising scale of the Gaoxin Runxin Fund [1] - The main investment areas of the fund include the healthcare sector, covering pharmaceuticals, medical devices, upstream supply chains and components, health food, synthetic biology, chemical materials, and consumer healthcare, with investments outside the healthcare sector not exceeding 10% of the fund's subscribed capital [1]